Please login to the form below

Not currently logged in
Email:
Password:

Linzess

This page shows the latest Linzess news and features for those working in and with pharma, biotech and healthcare.

China approves Ironwood Pharma’s IBS treatment

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion.

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... All eyes will now be on the performance

  • Pharma deals during April 2014 Pharma deals during April 2014

    Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including Linzess. Actavis has consented to Forest's acquisition of Furiex. The

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for ... The execution of a successful launch of Linzess should provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....